Abstract
The use of oseltamivir, widely stockpiled as one of the drugs for use in a possible avian influenza pandemic, has been reported to be associated with neuropsychiatric disorders and severe skin reactions, primarily in Japan. Here we identified a nonsynonymous SNP (single nucleotide polymorphism) in dbSNP database, R41Q, near the enzymatic active site of human cytosolic sialidase, a homologue of virus neuraminidase that is the target of oseltamivir. This SNP occurred in 9.29% of Asian population and none of European and African American population. Our structural analyses and Ki measurements using in vitro sialidase assays indicated that this SNP could increase the unintended binding affinity of human sialidase to oseltamivir carboxylate, the active form of oseltamivir, thus reducing sialidase activity. In addition, this SNP itself results in an enzyme with an intrinsically lower sialidase activity, as shown by its increased Km and decreased Vmax values. Theoretically administration of oseltamivir to people with this SNP might further reduce their sialidase activity. We note the similarity between the reported neuropsychiatric side effects of oseltamivir and the known symptoms of human sialidase-related disorders. We propose that this Asian-enriched sialidase variation caused by the SNP, likely in homozygous form, may be associated with certain severe adverse reactions to oseltamivir.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Varghese JN, Laver WG, Colman PM . Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 Å resolution. Nature 1983; 5912:35–40.
Bossart-Whitaker P, Carson M, Babu YS, Smith CD, Laver WG, Air GM . Three-dimensional structure of influenza A N9 neuraminidase and its complex with the inhibitor 2-deoxy 2,3-dehydro-N-acetyl neuraminic acid. J Mol Biol 1993; 232:1069–1083.
Burmeister WP, Ruigrok RW, Cusack S . The 2.2 Å resolution crystal structure of influenza B neuraminidase and its complex with sialic acid. EMBO J 1992; 11:49–56.
Janakiraman MN, White CL, Laver WG, Air GM, Luo M . Structure of influenza virus neuraminidase B/Lee/40 complexed with sialic acid and a dehydro analog at 1.8-Å resolution: implications for the catalytic mechanism. Biochemistry 1994; 33:8172–8179.
Garman E, Laver G . Controlling influenza by inhibiting the virus's neuraminidase. Curr Drug Targets 2004; 5:119–136.
Klumpp K, Graves BJ . Optimization of small molecule drugs binding to highly polar target sites: lessons from the discovery and development of neuraminidase inhibitors. Curr Top Med Chem 2006; 6:423–434.
Schunemann HJ, Hill SR, Kakad M, et al. WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus. Lancet Infect Dis 2007; 7:21–31.
Butler D . Wartime tactic doubles power of scarce bird-flu drug. Nature 2005; 438:6.
Edwards ET, Truffa MM . One-year post pediatric exclusivity postmarketing adverse events review drug: oseltamivir phosphate 2005; URL: http://www.fda.gov/ohrms/dockets/AC/05/briefing/2005-4180b_06_01_Tamiflu%20AE_reviewed.pdf.
Wilson JC, von Itzstein M . Recent strategies in the search for new anti-influenza therapies. Curr Drug Targets 2003; 4:389–408.
Wade RC . 'Flu' and structure-based drug design. Structure 1997; 5:1139–1145.
Varghese JN, Smith PW, Sollis SL, et al. Drug design against a shifting target: a structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase. Structure 1998; 6:735–746.
Zaccai NR, Maenaka K, Maenaka T, et al. Structure-guided design of sialic acid-based Siglec inhibitors and crystallographic analysis in complex with sialoadhesin. Structure (Camb) 2003; 11:557–567.
Chavas LM, Tringali C, Fusi P, et al. Crystal structure of the human cytosolic sialidase HsNEU2. Evidence for the dynamic nature of substrate recognition. J Biol Chem 2005; 280:469–475.
NCBI. Entrez SNP database. (2005). Available at URL: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=Snp&dopt=GEN&list_uids=2233385.
Tringali C, Papini N, Fusi P, et al. Properties of recombinant human cytosolic sialidase HsNEU2. The enzyme hydrolyzes monomerically dispersed GM1 ganglioside mol ecules.J Biol Chem 2004; 279:3169–3179.
Monti E, Preti A, Nesti C, Ballabio A, Borsani G . Expression of a novel human sialidase encoded by the NEU2 gene. Glycobiology 1999; 9:1313–1321.
Ho SN, Hunt HD, Horton RM, Pullen JK, Pease LR . Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 1989; 77:51–59.
Dai X, Chen Q, Lian M, et al. Systematic high-yield production of human secreted proteins in Escherichia coli. Biochem Biophys Res Commun 2005; 332:593–601.
Venerando B, Fiorilli A, Di Francesco L, et al. Cytosolic sialidase from pig brain: a 'protein complex' containing catalytic and protective units. Biochim Biophys Acta 1994; 1208:229–237.
Burk D, Lineweaver H . The influence of fixed nitrogen on azotobacter. J Bacteriol 1930; 19:389–414.
Kim CU, Lew W, Williams MA, et al. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. Am Chem Soc 1997; 119:681–690.
Seyrantepe V, Poupetova H, Froissart R, Zabot MT, Maire I, Pshezhetsky AV . Molecular pathology of NEU1 gene in sialidosis. Hum Mutat 2003; 22:343–352.
Boyzo A, Ayala J, Gutierrez R, Hernandez-R J . Neuraminidase activity in different regions of the seizing epileptic and non-epileptic brain. Brain Res 2003; 964:211–217.
Becker CG, Artola A, Gerardy-Schahn R, Becker T, Welzl H, Schachner M . The polysialic acid modification of the neural cell adhesion molecule is involved in spatial learning and hippocampal long-term potentiation. J Neurosci Res 1996; 45:143–152.
Rodriguez JA, Piddini E, Hasegawa T, Miyagi T, Dotti CG . Plasma membrane ganglioside sialidase regulates axonal growth and regeneration in hippocampal neurons in culture. J Neurosci 2001; 21:8387–8395.
Bowles SK, Lee W, Simor AE, et al. Oseltamivir compassionate use program group. Use of oseltamivir during influenza outbreaks in Ontario nursing homes, 1999–2000. J Am Geriatr Soc 2002; 50:608–616.
Moore ML, Chi MH, Zhou W, et al. Cutting edge: Oseltamivir decreases T cell GM1 expression and inhibits clearance of respiratory syncytial virus: potential role of endogenous sialidase in antiviral immunity. J Immunol 2007; 178:2651–2654.
Acknowledgements
We thank Drs Heping Cheng, Manyuan Long, Xiaole Liu, Michel Glauser, Amalio Telenti, and the anonymous reviewers for insightful suggestions. We thank Drs Luhua Lai and Zicai Liang for assistance with Ki measurements. This work is supported by the Hi-Tech Research and Development Program of China (863 Program, No. 2006AA02Z314) and National Keystone Basic Research Program of China (No. 2006CB910404) and China Ministry of Education 111 Project (No. B06001).
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Li, CY., Yu, Q., Ye, ZQ. et al. A nonsynonymous SNP in human cytosolic sialidase in a small Asian population results in reduced enzyme activity: potential link with severe adverse reactions to oseltamivir. Cell Res 17, 357–362 (2007). https://doi.org/10.1038/cr.2007.27
Published:
Issue date:
DOI: https://doi.org/10.1038/cr.2007.27
Keywords
This article is cited by
-
Genetic susceptibility in pneumoconiosis in China: a systematic review
International Archives of Occupational and Environmental Health (2023)
-
Assessment of adverse events related to anti-influenza neuraminidase inhibitors using the FDA adverse event reporting system and online patient reviews
Scientific Reports (2020)
-
Association study of genetic polymorphisms in proteins involved in oseltamivir transport, metabolism, and interactions with adverse reactions in Mexican patients with acute respiratory diseases
The Pharmacogenomics Journal (2020)
-
Association between common telomere length genetic variants and telomere length in an African population and impacts of HIV and TB
Journal of Human Genetics (2019)
-
Genetic differences among ethnic groups
BMC Genomics (2015)
